All AbMole products are for research use only, cannot be used for human consumption.
NUC-7738 is an effective pro-apoptotic agent in cancer cells with effects on the NF-kappaB pathway. NUC-7738 induced a cytotoxic effect on a wide range of cancer cell lines with an IC50 in the low uM range (<10 uM). NUC-7738 has been well tolerated and has demonstrated encouraging signals of anti-cancer activity in solid tumours.
| Molecular Weight | 568.52 |
| Formula | C26H29N6O7P |
| CAS Number | 2348493-39-8 |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Products |
|---|
| D-Allulose
D-Allulose (D-Psicose) is an ultralow-energy monosaccharide sugar. It is a C-3 epimer of D-fructose, and is present in small quantities in agricultural products and commercially-prepared carbohydrate complexes. |
| N,N-Dimethyltrifluoromethanesulfonamide
N,N-Dimethyltrifluoromethanesulfonamide (DMTMSA) is a trifluoromethanesulfonamide solvent. |
| Lucicebtide
Lucicebtide is a peptide antagonist of the transcription factor C/EBPβ, a key activator of the transcriptional program in immunosuppressive macrophages. Lucicebtide shows highly potent inhibition against C/EBPB-ATF5 association with IC50 of 24.6 nM in a competitive ELISA assay. |
| Eloralintide
Eloralintide (LY 3841136) is an AMYR agonist. |
| Gadoteric acid
Gadoteric acid is a macrocyclic, paramagnetic, gadolinium-based contrast agent that can be used for magnetic resonance imaging (MRI) of the brain, spine, and related tissues. Gadoteric acid is able to detect and visualize areas of blood-brain barrier disruption and abnormal vascular distribution. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
